Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, has demonstrated remarkable efficacy in clinical trials for weight loss and metabolic improvement. Beyond appetite suppression and glycemic control, questions remain about whether retatrutide directly increases energy expenditure and metabolic rate. This article examines the available evidence from clinical studies and mechanistic research to evaluate retatrutide's impact on metabolic rate.
Understanding Energy Expenditure Components
Total daily energy expenditure (TDEE) comprises three primary components: basal metabolic rate (BMR), accounting for 60-75% of total expenditure; activity energy expenditure (AEE); and the thermic effect of food (TEF). Additional components include non-exercise activity thermogenesis (NEAT) and adaptive thermogenesis in brown adipose tissue (BAT).
Traditional weight loss through caloric restriction typically reduces metabolic rate through adaptive mechanisms, a phenomenon that complicates long-term weight maintenance. The metabolic adaptation can persist years after weight loss, with reductions of 100-500 kcal/day below predicted values based on body composition [Rosenbaum et al. (2008). Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. DOI: 10.1093/ajcn/88.4.906].
Multi-receptor agonists like retatrutide may theoretically counter this adaptive response through glucagon-mediated increases in energy expenditure, potentially preserving or even increasing metabolic rate during weight loss. Understanding whether this occurs has significant implications for long-term weight maintenance outcomes.
Glucagon Receptor Activation and Thermogenesis
The glucagon receptor component of retatrutide represents the primary pathway through which the compound might increase energy expenditure. Glucagon promotes hepatic glucose production, lipolysis, and has documented thermogenic effects in preclinical models.
Studies in rodents demonstrate that glucagon receptor activation increases oxygen consumption and core body temperature. Glucagon enhances mitochondrial uncoupling in hepatocytes and may activate brown adipose tissue thermogenesis [Harney et al. (2023). Glucagon signals through the GLP-1 receptor to regulate energy expenditure. Nature Communications. DOI: 10.1038/s41467-023-36961-z].
In human studies, glucagon infusion has shown modest increases in resting energy expenditure, typically in the range of 5-10% above baseline. However, these effects are dose-dependent and may be offset by counter-regulatory mechanisms during chronic administration. The clinical significance of glucagon-mediated thermogenesis remains debated, particularly when integrated into a triple agonist system.
Retatrutide's balanced receptor activation profile is designed to leverage glucagon's thermogenic effects while mitigating potential hyperglycemic effects through GLP-1 and GIP receptor co-activation. This pharmacological balance may create a net positive effect on energy expenditure without adverse metabolic consequences.
Clinical Evidence from Phase 2 Trials
The Phase 2 trial of retatrutide in adults with obesity provided the most comprehensive clinical data available to date. This 48-week, randomized, double-blind study evaluated multiple dose levels (1, 4, 8, and 12 mg weekly) compared to placebo in 338 participants.
While the primary endpoints focused on weight loss (up to 24.2% at the 12 mg dose), secondary metabolic assessments provided insights into energy expenditure effects. Importantly, body composition analysis using DEXA scanning revealed preferential fat mass loss with relative preservation of lean body mass compared to expected ratios from dietary restriction alone [Jastreboff et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972].
The observed lean mass preservation (approximately 70% fat mass loss vs. 30% lean mass loss) suggests potential metabolic rate protection compared to traditional weight loss, where lean mass typically accounts for 20-30% of total weight loss. Since lean body mass is the primary determinant of resting metabolic rate, this preservation pattern implies reduced metabolic adaptation.
However, direct measurements of resting energy expenditure were not reported as trial outcomes, limiting definitive conclusions about metabolic rate changes. Indirect markers such as maintained physical activity levels and absence of reported fatigue may support preserved energy expenditure, but these remain speculative interpretations.
Comparative Effects: Retatrutide vs. Single and Dual Agonists
Comparing retatrutide's metabolic effects to single GLP-1 agonists and dual GIP/GLP-1 agonists provides important context. Semaglutide, a selective GLP-1 agonist, produces weight loss primarily through appetite suppression with limited direct effects on energy expenditure in human studies.
Tirzepatide, a dual GIP/GLP-1 agonist, demonstrated slightly better lean mass preservation than semaglutide in head-to-head comparisons, possibly due to GIP receptor-mediated effects on nutrient partitioning and adipose tissue metabolism. However, neither compound has shown consistent increases in measured resting metabolic rate in clinical trials.
The addition of glucagon receptor agonism in retatrutide theoretically provides the mechanistic basis for enhanced energy expenditure not present in these comparators. Preclinical head-to-head studies in diet-induced obese mice showed retatrutide produced greater weight loss than equipotent dual GIP/GLP-1 agonists, with evidence of increased energy expenditure in metabolic cage assessments.
Translating these preclinical advantages to human outcomes remains partially unvalidated due to limited direct energy expenditure measurements in published clinical trials. Future studies with comprehensive metabolic phenotyping will be essential to definitively establish retatrutide's effects on human metabolic rate.
Mechanisms Beyond Direct Thermogenesis
Beyond direct thermogenic effects, retatrutide may influence energy balance through multiple complementary mechanisms. GIP receptor activation enhances insulin sensitivity and may improve metabolic flexibility—the ability to efficiently switch between fat and carbohydrate oxidation depending on substrate availability.
Improved metabolic flexibility can optimize energy utilization and reduce metabolic inefficiency, effectively increasing functional energy expenditure without necessarily raising resting metabolic rate. This represents a distinct pathway from classical thermogenesis but achieves similar outcomes for weight management.
Additionally, GLP-1 receptor activation may preserve physical activity energy expenditure during weight loss. Studies of GLP-1 agonists suggest maintenance of activity levels compared to dietary restriction, where NEAT typically declines substantially. If retatrutide similarly maintains activity thermogenesis, this would contribute to total daily energy expenditure preservation.
The compound's effects on food reward processing and eating behavior may also indirectly influence energy balance sustainability. By reducing hedonic drive for palatable foods while maintaining satiation, retatrutide may prevent the compensatory increases in food preoccupation that typically accompany caloric restriction and metabolic adaptation.